港股创新药ETF（159567）涨超2%，中国两项减重降糖新药研究成果登上《自然》杂志！

Group 1 - The Hong Kong stock market indices rose significantly on December 19, with the biopharmaceutical sector leading the gains [1] - The Hong Kong Innovative Drug ETF (159567) increased by 2.31%, with a trading volume exceeding 656 million yuan and a turnover rate of over 7.9%, indicating active trading [1] - Notable individual stocks included InnoCare Pharma-B rising over 8%, Lepu Biopharma-B increasing over 5%, and 3SBio rising over 4% [1] Group 2 - Two Phase III clinical study results led by a Chinese research team on Marsduo peptide were published in the British journal Nature, focusing on its use in type 2 diabetes patients [1] - The studies, DREAMS-1 and DREAMS-2, were based on clinical data from Chinese patients and involved collaboration with leading experts and institutions in the field [1] - According to Dongfang Caifu Securities, China's innovative drug companies are entering a period of intensive pipeline harvest, with the market expected to exceed 400 billion yuan in 2024 [1] Group 3 - The number of approved domestic innovative drugs during the "14th Five-Year Plan" period is projected to be 113, which is 2.8 times that of the "13th Five-Year Plan" period [1] - The total amount of innovative drug License-out projects has reached a new record, with preclinical projects accounting for 68%, indicating growing global recognition of Chinese innovations [1] Group 4 - The Hong Kong Innovative Drug ETF closely tracks the National Index for Hong Kong Stock Connect Innovative Drugs, featuring leading stocks such as BeiGene, Innovent Biologics, and 3SBio [2] - The ETF includes several AI-driven pharmaceutical leaders, suggesting a high proportion of innovative drug companies, which may exhibit high elasticity as the AI-enabled innovative drug market expands [2]